Matthias Gromeier

This inventor holds 15 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 3 EPO patents. Top assignees: Duke University, The State University of New York, The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2001-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Gromeier. Retrieved from https://idiyas.com/inventor/matthias-gromeier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 7)

% Patents Active = 86.7

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 3.2

ph-index = 4

Forward Citations = 65(Granted Patents)

Location History:

Stony Brook, NY (US) (2001 - 2006)
Durham, NC (US) (2003 - 2023)

Company Filing History:

The State University of New York

patents

1 out of 3,696

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

where one patent can have more than one assignee

Years Active: 2001-2023

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11813298 - Oncolytic poliovirus for human tumors (2023-11-14),

2. 11506666 - Detection of CD-155, the poliovirus receptor (2022-11-22),

3. 11428691 - Methods for predicting tumor response to immunotherapy (2022-08-30),

4. 11406677 - Oncolytic poliovirus for human tumors (2022-08-09),

5. 11331343 - Compositions and methods for activating antigen presenting cells with chimeric poliovirus (2022-05-17),

6. 11065332 - Combination therapy of immunotoxin and checkpoint inhibitor (2021-07-20),

7. 10799543 - Oncolytic poliovirus for human tumors (2020-10-13),

8. 10744171 - Sequential anti-cancer treatment (2020-08-18),

9. 10744170 - Combination treatment (2020-08-18),

10. 10398743 - Oncolytic poliovirus for human tumors (2019-09-03),

11. 7968086 - Genetically stable enterovirus expression vector with replaced stem loop VI (2011-06-28),

12. 7147848 - Recombinant poliovirus for the treatment of cancer (2006-12-12),

13. 6518033 - Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment (2003-02-11),

14. 6464972 - Recombinant poliovirus for the treatment of cancer (2002-10-15),

15. 6264940 - Recombinant poliovirus for the treatment of cancer (2001-07-24),

Title: The Innovative Contributions of Matthias Gromeier

Introduction

Matthias Gromeier is a prominent inventor based in Durham, NC, known for his groundbreaking work in the field of oncolytic virotherapy. With a total of 15 patents to his name, Gromeier has made significant strides in developing innovative treatments for human tumors. His research focuses on utilizing modified polioviruses to target and destroy cancer cells, showcasing the potential of viral therapies in oncology.

Latest Patents

Gromeier's latest patents include the development of an oncolytic poliovirus for human tumors, which has demonstrated excellent anti-tumor effects in clinical settings. The mechanism of action involves both viral oncolysis and immune recruitment, leading to necrosis in the tumor area without any observed adverse effects. Another notable patent is the detection of CD-155, the poliovirus receptor, which has widespread applications in identifying tumor types. This reliable assay allows for the specific detection of CD155 in tissue sections, particularly in glioblastoma cells, indicating susceptibility to the poliovirus construct PVSRIPO. The assay is crucial for determining the appropriate use of PVSRIPO in oncolytic immunotherapy against various cancers.

Career Highlights

Throughout his career, Matthias Gromeier has worked with esteemed institutions such as Duke University and the State University of New York. His research has significantly advanced the understanding of oncolytic viruses and their therapeutic potential in treating cancer. Gromeier's innovative approaches have positioned him as a leading figure in the field of cancer research.

Collaborations

Gromeier has collaborated with notable colleagues, including Darell D. Bigner and John Howard Sampson. These partnerships have further enriched his research and contributed to the development of effective cancer therapies.

Conclusion

Matthias Gromeier's contributions to the field of oncolytic virotherapy are remarkable and continue to influence cancer treatment strategies. His innovative patents and collaborative efforts highlight the importance of research in developing effective therapies for challenging diseases.

Profile summary based on public USPTO records.